Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
NATIONAL KIDNEY FOUNDATION

2. Address

Address1
1634 Eye Street, NW
 Address2
​Suite 1050
City
Washington
 State
DC
 Zip Code
20006
 Country
USA

3. Principal place of business (if different than line 2)

City
​New York City
 State
​NY
 Zip Code
​10016
 Country
​USA
4a. Contact Name b. Telephone Number c. E-mail
​Mr.
​TROY ZIMMERMAN
​7034312218
​troyz@kidney.org
5. Senate ID#
​28105-12
7. Client Name Self Check if client is a state or local government or instrumentality
​NATIONAL KIDNEY FOUNDATION
6. House ID#
​306830000
TYPE OF REPORT 8. Year
​2023
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​
$5,000 or more $
​300,000.00
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: TROY ZIMMERMAN
 Date
4/20/2023 3:24:53 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

FY2023 and FY 2024 Appropriations for the Department of Health and Human Services, including CDC, NIH and HRSA.

Funding increases for CDC Chronic Kidney Disease Initiative.

Funding increase for kidney disease research at the National Institute of Diabetes and Digestive and Kidney Diseases.

Funding for organ donation and transplant activities under HRSA and HHS.

FY2023 and FY 2024 funding for Indian Health Service.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Natl Institutes of Health (NIH), Health Resources & Services Administration (HRSA), Health & Human Services - Dept of (HHS), Indian Health Service

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Troy
Zimmerman
​
​
Sharon
Pearce
​
​
Lauren
Drew
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Living Donor Protection Act (not yet introduced in 118th Congress), to prohibit discrimination in the issuing, pricing and benefits amount of life, disability, or long-term care insurance policies for living organ donors.

Initiatives and activities to increase, improve, and facilitate organ donation and transplantation, including equity in transplant access.

Activities regarding HHS Advancing American Kidney Health Initiative.

Activities to address COVID-19 and the needs of dialysis patients and kidney transplant recipients, including but not limited to vaccinations and access to COVID medications and treatments.

Activities to address ethnic, racial and social disparities in health and health care access, including comments to the National Institute of Diabetes and Digestive and Kidney Diseases working group Health Disparities and Health Equities Research draft report.

Telemedicine and telehealth access.

Affordable Care Act access, utilization and Essential Health Benefits.

Prescription drug pricing and access.


17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Agency for Healthcare Research & Quality (AHRQ)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Troy
Zimmerman
​
​
Sharon
Pearce
​
​
Lauren
Drew
​
​
Morgan
Reid
​
​
Ignacio
Alvarez
​
​
Ivory
Harding
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Access and utilization of home dialysis for Medicare beneficiaries, including draft legislation to authorize Medicare reimbursement for staff-assisted home dialysis.

Support for Medicare Part D Protected Classes.

Medicare activities and coverage for COVID-19 patients.

Medicare/Medicaid dual eligibility.

Comments to Senate HELP Committee on workforce shortages.

Treat and Reduce Obesity Act (pending introduction).

Comments to ESRD Quality Incentive Program Study of Quality and Patient Experience.

Comments on ESRD Medical Evidence Report (CMS-2728 form).

Comments on Proposed Rule/RFI: Advancing Interoperability and Improving Prior Authorization.

Comments on Advanced Notice for Calendar Year 2024 Medicare Advantage Capitation Rates and Part C and Part D Payment.

Proposed Rule for Contract Year 2024 Policy Changes to Medicare Advantage and Prescription Drug Programs.




17. House(s) of Congress and Federal agencies Check if None

Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Troy
Zimmerman
​
​
Sharon
Pearce
​
​
Lauren
Drew
​
​
Morgan
Reid
​
​
Ignacio
Alvarez
​
​
Ivory
Harding
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​
​
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)